CN100423790C - 内含抗生素聚甲基丙烯酸甲酯骨骼粘固粉 - Google Patents
内含抗生素聚甲基丙烯酸甲酯骨骼粘固粉 Download PDFInfo
- Publication number
- CN100423790C CN100423790C CNB2005101135350A CN200510113535A CN100423790C CN 100423790 C CN100423790 C CN 100423790C CN B2005101135350 A CNB2005101135350 A CN B2005101135350A CN 200510113535 A CN200510113535 A CN 200510113535A CN 100423790 C CN100423790 C CN 100423790C
- Authority
- CN
- China
- Prior art keywords
- antibiotics
- particles containing
- polymethyl methacrylate
- cement
- antibiotic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/06—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0015—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/16—Macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
Abstract
本发明描述一种内含抗生素的聚甲基丙烯酸甲酯(PMMA)骨骼粘固粉,带有一粉状材料和一液态组分,其特征在于:在粉状组分材料中含有0.1-5.0%质量比的溶于水的玻璃状透明抗生素颗粒,其颗粒直径的范围在50-1000μm;抗生素颗粒由互相结合的玻璃状透明抗生素原始微粒组成,而抗生素原始微粒的粒径范围在1-70μm之间。
Description
技术领域
本发明涉及某种粉状材料和某种液态物质调制成的,内含抗生素的聚甲基丙烯酸甲酯(PMMA)骨骼粘固粉。
背景技术
内含抗菌素的聚甲基丙烯酸甲酯骨骼粘固粉,自20世纪60年代以来由于H.W.Buchholz和库尔策(Kulzer)公司的论文发表而为人所知(W.Ege,K.-D Kuehn:骨骼粘固粉的工业化生产-25年来积累的经验;发表在:骨骼粘固粉及骨骼粘固技术;Eds.G.H.I.M.Welenkamp,D.W.Murray,海德堡Springer出版社,2001.,出版:H..W.Buchholz,E.Engelbrecht:关于若干种抗菌素与Palacos塑料树脂混合后的长期效用,Chirurg41(1970)511-515)。这种PMMA粘固粉拥有广阔的市场,并已大量用于内置式假肢的固定(K.-D.Kuehn:内置假肢技术中的骨骼粘固粉:市售PMMA粘固粉物理化学性能主要参数的比较,柏林,海德堡,纽约Springer出版社,2001)。在PMMA骨骼粘固粉中不可缺少的抗菌素,在假肢植入后,在骨骼粘固粉/骨骼的相接界面以不同的速度释放出来,并且能够遏制界面上的细菌繁殖。如果能够尽最大可能有效释放出抗菌素,则所用抗生素的最低抗菌浓度(MBK),完全可以达到临床中骨骼粘固粉/骨骼相接界面上的主要要求,并且还将超过。至今为止,通常用于PMMA骨骼粘固粉中的抗菌素是疗效广泛的庆大霉素。
发明内容
本发明的任务,是基于开发一种能够极其有效地释放抗生素的PMMA粘固粉而提出的。这种粘固粉中的抗菌素能在骨骼粘固粉硬化后24小时内从骨骼粘固粉中大量地释放出来。
本发明的任务是通过权利要求1陈述的内容来完成的。本发明派生的应用效益,将在专利权限中从属要求中陈述。本发明的PMMA骨骼粘固粉具有下列特性:在粉状材料中含有0.1-5.0%质量比的溶于水的玻璃状透明抗生素颗粒;这种抗生素颗粒的粒径范围在50-1000μm,首选范围在63-900μm之间;抗生素颗粒由互相结合的玻璃状透明抗生素原始微粒组成;抗生素原始微粒的粒径范围在1-70μm之间;
对于配置PMMA骨骼粘固粉的粉状材料,可以理解为由至少一种粉状聚甲基丙烯酸甲酯或者一种由甲基丙烯酸甲酯和丙烯酸甲酯的共聚物,一种粉状X射线阻透剂,如二氧化锆和/或硫酸钡和一种高效引发剂,如过氧化二苯甲酰组成的混合物。在必要时,可以在粉状材料的组成物中添加一种可以药用的颜料进行着色。粉状材料在与甲基丙烯酸甲酯(MMA)构成的液态物质进行混合后,成为一团类似塑料的塑性材料。由于所用甲基丙烯酸甲酯激烈的聚合作用,经过几分钟后,这团塑性材料即自行硬化。在前面提及的甲基丙烯酸甲酯中,溶解有一种如N,N-二甲基-p-甲苯胺这样的高效引发剂。
对于玻璃状透明抗生素颗粒的概念,可以理解为由一种或若干种抗菌素组成的颗粒。这种抗菌素颗粒在光学显微镜下不呈现能够看清的晶状结构,但是呈透明状和/或不透明状。这种抗生素颗粒,具有玻璃状透明的表观特性。此外,这种抗生素颗粒的粒径约在50-1000μm之间,并且由互相牢固结合的玻璃状透明抗生素原始微粒构成。对于互相牢固结合的玻璃状透明抗生素原始微粒的概念,可以理解为由抗菌素原始微粒互相结合而成的颗粒是如此的稳定,以致可以与具有腐蚀性的粉状材料,如二氧化锆和硫酸钡一起研磨,或者利用合适的设备进行混合都毫无问题,并且不会导致抗菌素颗粒大量分解成原始的抗菌素微粒。同样在这种情况下,所谓玻璃状透明,也就是在光学显微镜下可以看清抗菌素原始微粒中没有结晶体,并且显示抗菌素原始微粒没有自行生成结晶体。此外,上述概念还说明,抗菌素原始微粒呈透明状和/或不透明状。
按照本发明制取的PMMA骨骼粘固粉,在37℃的玻基(vitro)条件下,能够最大量地释放抗菌素。
依照本发明制得的粘固粉的优越性在于,玻璃状透明原始微粒组成的抗生素颗粒界面,在光学显微镜下,只能够看清抗菌素颗粒的表面,也就是说,在光学显微镜下,这种抗菌素颗粒的表面特性几乎已经接近于抗生素原始微粒的表面性能。
符合本发明目的要求的抗菌素是,抗生素的颗粒,至少由氨基糖苷抗菌素基团,林可酰胺抗菌素基团,氟喹诺酮抗菌素基团,糖肽抗菌素基团或硝基咪唑中的一个代表性的基团构成。由硝基咪唑基团构成的抗菌增效化疗药物,也可以直接理解为抗菌素。化疗药物主要用于杀灭厌氧菌。
符合本发明目的要求的抗菌素是,抗生素的颗粒,首选的由硫酸庆大霉素,盐酸庆大霉素,硫酸阿米卡星,盐酸阿米卡星,硫酸妥布霉素,盐酸妥布霉素,盐酸克林霉素,盐酸林可胺,莫西沙星,环丙沙星,替考拉宁,万古霉素,雷莫拉宁,甲硝唑,替硝唑或阿米硝唑,或上述化合物的混合物构成。除了溶解于水中的抗菌素盐和抗菌素外,溶解于水中的也可以还有少量的可溶性盐状抗菌素,例如帕米酸盐(Palmitate),肉豆蔻酸盐,月桂酸盐。盐状抗菌素附着性结合在抗生素颗粒中。另外,也可能有由恶唑烷酮,比如利奈唑胺基团组成的抗菌素结合进抗菌素颗粒内。
此外,本发明产品还具有在必要时向抗生素颗粒中另外添加辅助材料,如聚乙烯吡咯烷酮和/或聚乙烯乙二醇和/或聚乙烯氧化物和/或麦芽糖和/或山梨醇和/或甘露醇的优点。通过这种辅助材料,可以使抗生素颗粒获得良好的稳定性。通过其它毒理学可接受的聚合体,如明胶,胶原,右旋糖酐,使抗生素颗粒获得稳定性的方法,同样属于本专利的发明范围之内。
附图说明
图1为符合本发明要求的粒径范围在125-250μm的典型抗菌素硫酸庆大霉素颗粒图。
具体实施方式
本发明将通过下列3个实例加以阐述,但是本发明内容并不局限于所举实例。
实例1:
在附图1中所示的为符合本发明要求的粒径范围在125-250μm的硫酸庆大霉素颗粒图。
具体实施方式
本发明将通过下列3个实例加以阐述,但是本发明内容并不局限于所举实例。
实例1:
在附图1中所示的为符合本发明要求的粒径范围在125-250μm的典型抗菌素硫酸庆大霉素颗粒。图中抗菌素原始微粒表面结构清晰可辨。
实例2:
为了检验按照本专利方法制得的PMMA骨骼粘固粉,让我们做一个试样体的释放试验。按照下列方式进行试样体的制备:首先每次取40.0克Palacos牌骨骼粘固粉(由Heraeus Kulzer公司生产)的粉状材料,并采用下列方案进行混合:
方案a)0.8克粒径范围<63μm的硫酸庆大霉素;
方案b)0.8克原始微粒构成的粒径范围在63-250μm的玻璃状透明硫酸庆大霉素颗粒;
方案c)0.8克原始微粒构成的粒径范围在500-900μm的玻璃状透明硫酸庆大霉素颗粒;
方案d)0.04克原始微粒构成的粒径范围在63-250μm的玻璃状透明硫酸庆大霉素颗粒。
然后,把这种改性的粉状材料与每次20.0克的单体材料进行混合。由此制得一块内部掏空的绿色料团,并在短短的几分钟后就地硬化。以此制得的这个圆筒形的试样体,高1厘米,直径2.5厘米。为每一个粘固粉的方案制备5个这样的试样体。将这些试样体分别浸入20毫升37℃的精馏水中。每天全部倒出吸收释放物的介质(水),并测定其中所含庆大霉素的量。然后,把这些试样体重新分别存放到20毫升37℃的水中。再用Abott公司制造的TDX分析仪测定释放的庆大霉素。与试样体在吸收释放物介质中存放时间相应的,每克试样体中庆大霉素基体每次释放的质量,请见下表所列:
实例3:
为了检验按照本专利方法制得的PMMA骨骼粘固粉,让我们做一个试样体的释放试验。按照下列方式进行试样体的制备:首先每次取40.0克Palacos牌骨骼粘固粉(由Heraeus Kulzer公司生产)的粉状材料,并采用下列方案进行混合:
方案a)1.6克原始微粒构成的粒径范围在63-250μm的玻璃状透明硫酸庆大霉素万古霉素颗粒(0.8g硫酸庆大霉素+0.8g万古霉素颗粒);
方案b)0.8克原始微粒构成的粒径范围在63-250μm的玻璃状透明盐酸克林霉素颗粒;
方案c)1.6克原始微粒构成的粒径范围在63-250μm的玻璃状透明硫酸庆大霉素甲硝唑颗粒(0.8g硫酸庆大霉素+0.8g甲硝唑颗粒);
方案d)1.6克原始微粒构成的粒径范围在63-250μm的玻璃状透明环丙沙星硫酸妥布霉素颗粒(0.8g环丙沙星+0.8g硫酸妥布霉素颗粒)。
然后,把这种改性的粉状材料与每次20.0克的单体材料进行混合。由此制得一块内部掏空的绿色料团,并在短短的几分钟后就地硬化。以此制得的这个圆筒形的试样体,高1厘米,直径2.5厘米。为每一个粘固粉的方案制备5个这样的试样体。将这些试样体分别浸入20毫升37℃的精馏水中。每天全部倒出吸收释放物的介质(水),并测定其中所含庆大霉素的量。然后,把这些试样体重新分别存放到20毫升37℃的水中。再用Abott公司制造的TDX分析仪测定释放的庆大霉素和万古霉素。盐酸克林霉素用
Claims (8)
1. 内含抗生素的聚甲基丙烯酸甲酯骨骼粘固粉,带有一粉状材料和一液态组分,其特征在于:在粉状组分材料中含有0.1-5.0%质量比的溶于水的玻璃状透明抗生素颗粒;抗生素颗粒由互相结合的玻璃状透明抗生素原始微粒组成;抗生素原始微粒的粒径范围在1-70μm之间,
所述由抗菌素原始微粒互相结合而成的颗粒是稳定的,其能够与具有腐蚀性的粉状材料一起研磨,或者利用设备进行混合,不会导致抗菌素颗粒大量分解成原始的抗菌素微粒。
2. 根据权利要求1的聚甲基丙烯酸甲酯骨骼粘固粉,其特征是抗生素颗粒直径的范围在50-1000μm。
3. 根据权利要求1的聚甲基丙烯酸甲酯骨骼粘固粉,其特征是具有玻璃状透明抗生素原始最微小颗粒之间的边界只能在光学显微镜下通过这种微粒组成的抗生素颗粒表面来分辨。
4. 根据权利要求1,2或3的聚甲基丙烯酸甲酯骨骼粘固粉,其特征是抗生素颗粒至少由氨基糖苷抗菌素基团、林可酰胺抗菌素基团、氟喹诺酮抗菌素基团、糖肽抗菌素基团或硝基咪唑中的一种基团组成。
5. 根据权利要求1-3中任一权利要求所述的聚甲基丙烯酸甲酯骨骼粘固粉,其特征是抗生素颗粒由硫酸庆大霉素,盐酸庆大霉素,硫酸阿米卡星,盐酸阿米卡星,硫酸妥布霉素,盐酸妥布霉素,盐酸克林霉素,盐酸林可胺,莫西沙星,环丙沙星,替考拉宁,万古霉素,雷莫拉宁,甲硝唑,替硝唑或阿米硝唑,或上述化合物的混合物组成。
6. 根据权利要求4所述的聚甲基丙烯酸甲酯骨骼粘固粉,其特征是抗生素颗粒由硫酸庆大霉素,盐酸庆大霉素,硫酸阿米卡星,盐酸阿米卡星,硫酸妥布霉素,盐酸妥布霉素,盐酸克林霉素,盐酸林可胺,莫西沙星,环丙沙星,替考拉宁,万古霉素,雷莫拉宁,甲硝唑,替硝唑或阿米硝唑,或上述化合物的混合物组成。
7. 根据权利要求1-3中任一权利要求所述的聚甲基丙烯酸甲酯骨骼粘固粉,其特征是抗生素颗粒含有另外作为辅助材料加入的聚乙烯吡咯烷酮和/或聚乙烯乙二醇和/或聚乙烯氧化物和/或麦芽糖和/或山梨醇和/或甘露醇。
8. 根据权利要求4所述的聚甲基丙烯酸甲酯骨骼粘固粉,其特征是抗生素颗粒含有另外作为辅助材料加入的聚乙烯吡咯烷酮和/或聚乙烯乙二醇和/或聚乙烯氧化物和/或麦芽糖和/或山梨醇和/或甘露醇。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102004049121.6 | 2004-10-07 | ||
DE102004049121A DE102004049121B4 (de) | 2004-10-07 | 2004-10-07 | Antibiotikum-/Antibiotika enthaltender PMMA-Knochenzement |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1768867A CN1768867A (zh) | 2006-05-10 |
CN100423790C true CN100423790C (zh) | 2008-10-08 |
Family
ID=35853155
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2005101135350A Active CN100423790C (zh) | 2004-10-07 | 2005-10-08 | 内含抗生素聚甲基丙烯酸甲酯骨骼粘固粉 |
Country Status (13)
Country | Link |
---|---|
US (1) | US20060292199A1 (zh) |
EP (1) | EP1649874B1 (zh) |
JP (1) | JP2006102512A (zh) |
CN (1) | CN100423790C (zh) |
AT (1) | ATE525097T1 (zh) |
AU (1) | AU2005205817B2 (zh) |
BR (1) | BRPI0504593B1 (zh) |
CA (1) | CA2517643C (zh) |
DE (1) | DE102004049121B4 (zh) |
DK (1) | DK1649874T3 (zh) |
ES (1) | ES2371917T3 (zh) |
PL (1) | PL1649874T3 (zh) |
ZA (1) | ZA200508059B (zh) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8415406B2 (en) * | 2005-07-22 | 2013-04-09 | Howmedica Osteonics Corp. | Setting time indicator for acrylic bone cement |
DE102005061290B4 (de) * | 2005-12-20 | 2021-03-18 | Heraeus Medical Gmbh | Verfahren zur Herstellung von Antibiotikum-/Antibiotika-Partikeln und deren Verwendung |
DE102007004968B4 (de) | 2007-01-26 | 2011-03-10 | Heraeus Kulzer Gmbh | Revisions-Polymethylmethacrylat-Knochenzement |
DE102007015698B4 (de) | 2007-03-27 | 2009-05-14 | Innotere Gmbh | Implantatmaterial auf Basis eines Polymersystems und dessen Verwendung sowie Applikationsset |
WO2009143236A1 (en) * | 2008-05-20 | 2009-11-26 | Albert Einstein Healthcare Network | Compositions and methods for the treatment of skeletal metastatic lesions and fractures |
DE102009004368A1 (de) * | 2009-01-08 | 2010-07-15 | Heraeus Kulzer Gmbh | Dentalmaterialien enthaltend antimikrobielle Wirkstoffe zur Verhinderung von Plaque-Anlagerungen |
FR2942723B1 (fr) * | 2009-03-05 | 2011-06-10 | Teknimes | Ciment pour comblement osseux |
KR101031864B1 (ko) * | 2009-11-06 | 2011-05-02 | (주)인젝타 | 페이스트-분말의 이원성 고분자계 골 시멘트 및 이의 투입장치 |
WO2011068481A1 (en) * | 2009-12-04 | 2011-06-09 | Agency For Science, Technology And Research | Nanostructured material formulated with bone cement for effective antibiotic delivery |
US8673018B2 (en) | 2010-02-05 | 2014-03-18 | AMx Tek LLC | Methods of using water-soluble inorganic compounds for implants |
US8834772B2 (en) | 2011-12-07 | 2014-09-16 | Biomet Manufacturing, Llc | Antimicrobial methacrylate cements |
KR101432207B1 (ko) * | 2013-05-15 | 2014-08-21 | 한국세라믹기술원 | 카페인산 페네틸 에스테르 함유 항균 골 시멘트 조성물 및 이의 제조방법 |
DE102014104676A1 (de) * | 2014-04-02 | 2015-10-08 | Heraeus Medical Gmbh | Fosfomycin-Zubereitung, ein Verfahren zur Herstellung der Zubereitung und ein die Zubereitung enthaltendes Polymethylmethacrylat-Knochenzementpulver |
DE102014218913A1 (de) | 2014-09-19 | 2016-03-24 | Heraeus Medical Gmbh | Verfahren zur Herstellung eines antibiotischen Polymehtylmethacrylat-Knochenzementpulvers und ein antibiotisches Polymethtylmethacrylat-Knochenzementpulver |
ES2566232B2 (es) * | 2014-10-09 | 2016-11-07 | Lvd Biotech S.L. | Formulaciones de cementos óseos con acción antibiótica |
CN107625993A (zh) * | 2017-09-01 | 2018-01-26 | 苏州大学 | 一种具有抗菌和生物相容性的骨水泥及其制备方法 |
US20210052779A1 (en) * | 2018-04-13 | 2021-02-25 | University Of Virginia Patent Foundation | Compositions and methods for preparing and using non-immunogenic fast annealing microporous annealed particle hydrogels |
CN110101906B (zh) * | 2019-05-31 | 2021-08-06 | 西安理工大学 | 一种可注射型pmma抗生素骨水泥及其制备方法 |
CN110975003A (zh) * | 2019-12-31 | 2020-04-10 | 苏州众泽医疗科技有限公司 | 一种治疗骨科感染的抗生素骨水泥 |
CN111317861B (zh) * | 2020-03-20 | 2022-02-18 | 西安理工大学 | 一种可控释抗生素膨胀丙烯酸骨水泥及其制备方法 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1349259A (en) * | 1970-05-06 | 1974-04-03 | Scherico Ltd | Adhesive cement and method for its production |
US5258420A (en) * | 1987-07-30 | 1993-11-02 | Pfizer Hospital Products Group, Inc. | Bone cement for sustained release of substances |
EP0701824A2 (de) * | 1994-09-17 | 1996-03-20 | MERCK PATENT GmbH | Verfahren zur Herstellung von wirkstoffhaltigen Knochenzementen |
US6160033A (en) * | 1996-08-22 | 2000-12-12 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Process for producing bone cement containing active substances |
US6494717B1 (en) * | 1998-09-24 | 2002-12-17 | Advantage Dental Products, Inc. | Calcified tissue facing preparation containing an antimicrobial agent |
CN1512898A (zh) * | 2001-05-30 | 2004-07-14 | ̩ | 含有涂层的不透射线的颗粒的骨粘固粉及其制备 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2552070C3 (de) * | 1975-11-20 | 1981-06-19 | Beiersdorf Ag, 2000 Hamburg | Verfahren zur Herstellung einer für chirurgische Zwecke verwendbaren Masse |
DE3245956A1 (de) * | 1982-12-11 | 1984-06-14 | Beiersdorf Ag, 2000 Hamburg | Chirurgisches material |
DE3513938A1 (de) * | 1985-04-18 | 1986-10-23 | Merck Patent Gmbh, 6100 Darmstadt | Cytostatikahaltiges pharmakadepot |
FR2673843B1 (fr) * | 1991-03-14 | 1995-01-13 | Centre Nat Rech Scient | Composition pharmaceutique implantable, bioresorbable a base de poly(acide lactique), destinee a mettre en óoeuvre une antibiotherapie interne locale. |
US5334626A (en) * | 1992-07-28 | 1994-08-02 | Zimmer, Inc. | Bone cement composition and method of manufacture |
DE4435680A1 (de) * | 1994-10-06 | 1996-04-11 | Merck Patent Gmbh | Poröse Knochenersatzmaterialien |
US5650408A (en) * | 1995-06-07 | 1997-07-22 | Karanewsky; Donald S. | Thiazolo benzazepine containing dual action inhibitors |
US6689823B1 (en) * | 1999-03-31 | 2004-02-10 | The Brigham And Women's Hospital, Inc. | Nanocomposite surgical materials and method of producing them |
DE19918295C2 (de) * | 1999-04-22 | 2003-09-25 | Coripharm Medizinprodukte Gmbh | Kompatibles Implantat-Baustein-System in Form eines Baukastensystems für Implantationsmaterialien, Verfahren zur Herstellung derselben und ihre Verwendung |
US6579533B1 (en) * | 1999-11-30 | 2003-06-17 | Bioasborbable Concepts, Ltd. | Bioabsorbable drug delivery system for local treatment and prevention of infections |
DE10129842C1 (de) * | 2001-06-15 | 2003-04-24 | Bam Bundesanstalt Matforschung | Verfahren zur Herstellung eines bioaktiven Knochenzements und Knochenzement-Kit |
-
2004
- 2004-10-07 DE DE102004049121A patent/DE102004049121B4/de not_active Expired - Fee Related
-
2005
- 2005-08-30 CA CA2517643A patent/CA2517643C/en not_active Expired - Fee Related
- 2005-09-05 AU AU2005205817A patent/AU2005205817B2/en active Active
- 2005-09-23 AT AT05020738T patent/ATE525097T1/de active
- 2005-09-23 DK DK05020738.0T patent/DK1649874T3/da active
- 2005-09-23 EP EP05020738A patent/EP1649874B1/de active Active
- 2005-09-23 ES ES05020738T patent/ES2371917T3/es active Active
- 2005-09-23 US US11/234,034 patent/US20060292199A1/en not_active Abandoned
- 2005-09-23 PL PL05020738T patent/PL1649874T3/pl unknown
- 2005-10-06 BR BRPI0504593A patent/BRPI0504593B1/pt not_active IP Right Cessation
- 2005-10-06 ZA ZA200508059A patent/ZA200508059B/en unknown
- 2005-10-06 JP JP2005293913A patent/JP2006102512A/ja active Pending
- 2005-10-08 CN CNB2005101135350A patent/CN100423790C/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1349259A (en) * | 1970-05-06 | 1974-04-03 | Scherico Ltd | Adhesive cement and method for its production |
US5258420A (en) * | 1987-07-30 | 1993-11-02 | Pfizer Hospital Products Group, Inc. | Bone cement for sustained release of substances |
EP0701824A2 (de) * | 1994-09-17 | 1996-03-20 | MERCK PATENT GmbH | Verfahren zur Herstellung von wirkstoffhaltigen Knochenzementen |
US6160033A (en) * | 1996-08-22 | 2000-12-12 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Process for producing bone cement containing active substances |
US6494717B1 (en) * | 1998-09-24 | 2002-12-17 | Advantage Dental Products, Inc. | Calcified tissue facing preparation containing an antimicrobial agent |
CN1512898A (zh) * | 2001-05-30 | 2004-07-14 | ̩ | 含有涂层的不透射线的颗粒的骨粘固粉及其制备 |
Also Published As
Publication number | Publication date |
---|---|
BRPI0504593A (pt) | 2006-05-23 |
CA2517643C (en) | 2010-08-17 |
CN1768867A (zh) | 2006-05-10 |
US20060292199A1 (en) | 2006-12-28 |
ZA200508059B (en) | 2006-07-26 |
ATE525097T1 (de) | 2011-10-15 |
BRPI0504593B1 (pt) | 2016-08-23 |
DE102004049121B4 (de) | 2008-01-10 |
AU2005205817B2 (en) | 2007-07-12 |
AU2005205817A1 (en) | 2006-04-27 |
EP1649874B1 (de) | 2011-09-21 |
DE102004049121A1 (de) | 2006-04-13 |
PL1649874T3 (pl) | 2012-02-29 |
AU2005205817B8 (en) | 2006-04-27 |
ES2371917T3 (es) | 2012-01-11 |
EP1649874A3 (de) | 2006-09-06 |
CA2517643A1 (en) | 2006-04-07 |
JP2006102512A (ja) | 2006-04-20 |
EP1649874A2 (de) | 2006-04-26 |
DK1649874T3 (da) | 2011-12-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100423790C (zh) | 内含抗生素聚甲基丙烯酸甲酯骨骼粘固粉 | |
CN101229391B (zh) | 骨骼修复用聚甲基丙烯酸甲酯粘固剂 | |
CA1282330C (en) | Drug depot containing cytostatics | |
JP2001503290A (ja) | 活性化合物を含有する骨用セメントの製造方法 | |
Overstreet et al. | In situ forming, resorbable graft copolymer hydrogels providing controlled drug release | |
CN103566416B (zh) | 糊状骨水泥 | |
CN103223188A (zh) | 糊状骨水泥 | |
Lee et al. | Polydopamine-laced biomimetic material stimulation of bone marrow derived mesenchymal stem cells to promote osteogenic effects | |
AU2009266110A1 (en) | PMMA paste | |
CN101011598A (zh) | 一种生物活性的止血、骨缺损修复材料 | |
CN114854161A (zh) | 一种抗菌除异味高吸水树脂及其制备方法 | |
CN112618797B (zh) | 一种交联抗生素的特定脱矿细胞外基质支架的制备方法 | |
Long et al. | Controlled release of alendronate from polymeric films | |
Hong et al. | Biodegradable calcium phosphate bone cement incorporated with antibiotics | |
Lin et al. | A Review on the Promising Antibacterial Agents in Bone Cement-from Past to Current Insights | |
Chen et al. | An antibacterial dental light-cured glass-ionomer cement with improved hardness | |
JP2000254220A (ja) | 生体活性セメント組成物 | |
Weber et al. | Mechanical evaluation of Poly-ε-caprolactone and biosilicate® composites | |
Xu et al. | Injectable isoniazid-loaded bone cement based on hydrazone bond achieving long-term release and decent mechanical property | |
JP2001164073A (ja) | 生体活性セメント組成物 | |
JP2000086419A (ja) | 生体活性セメント組成物 | |
JP2002085548A (ja) | 生体活性セメント組成物 | |
JP2001293080A (ja) | 生体活性セメント組成物 | |
JPH01230367A (ja) | 医療用硬化組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: HERAEUS MEDICAL CO., LTD. Free format text: FORMER OWNER: HERAEUS KULZER GMBH Effective date: 20140331 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20140331 Address after: Germany's Maxwell Patentee after: Heraeus Medical GmbH Address before: Hanau, Germany Patentee before: Heraeus Kulzer GmbH |